Dalam Ly

List of Publications by Year
in descending order

30 papers	1,299 citations	516710 16 h-index	610901 24 g-index
36 all docs	36 docs citations	36 times ranked	1774 citing authors

#	Article	IF	Citations
1	Tumor-Associated Regulatory T Cell Expression of LAIR2 Is Prognostic in Lung Adenocarcinoma. Cancers, 2022, 14, 205.	3.7	10
2	CRISPR screen identifies genes that sensitize AML cells to double-negative T-cell therapy. Blood, 2021, 137, 2171-2181.	1.4	23
3	Affinity-matured HLA class II dimers for robust staining of antigen-specific CD4+ T cells. Nature Biotechnology, 2021, 39, 958-967.	17.5	15
4	Landscape mapping of shared antigenic epitopes and their cognate TCRs of tumor-infiltrating T lymphocytes in melanoma. ELife, 2020, 9, .	6.0	13
5	Somatic Alteration Burden Involving Non-Cancer Genes Predicts Prognosis in Early-Stage Non-Small Cell Lung Cancer. Cancers, 2019, 11, 1009.	3.7	2
6	Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15. , 2019, 7, 17.		38
7	Targeting late-stage non-small cell lung cancer with a combination of DNT cellular therapy and PD-1 checkpoint blockade. Journal of Experimental and Clinical Cancer Research, 2019, 38, 123.	8.6	32
8	Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer. Cellular and Molecular Immunology, 2019, 16, 6-18.	10.5	322
9	Allogeneic Human Double Negative T Cells as a Novel Immunotherapy for Acute Myeloid Leukemia and Its Underlying Mechanisms. Clinical Cancer Research, 2018, 24, 370-382.	7.0	57
10	P1.04-02 Targeting Established Lung Cancer Through Combination of DNT Cellular Therapy with PD1 Checkpoint Blockade. Journal of Thoracic Oncology, 2018, 13, S525-S526.	1.1	0
11	Infusion of *ex-vivo* expanded human TCR-αβ+ double-negative regulatory T cells delays onset of xenogeneic graft-*versus*-host disease. Clinical and Experimental Immunology, 2018, 193, 386-399.	2.6	19
12	P2.03b-089 CD1C in Lung Adenocarcinoma: Prognosis and Cellular Origin. Journal of Thoracic Oncology, 2017, 12, S990.	1.1	0
13	Role for High-Affinity IgE Receptor in Prognosis of Lung Adenocarcinoma Patients. Cancer Immunology Research, 2017, 5, 821-829.	3.4	14
14	Abstract A64: Mast cell expressed FcεR beta subunit (MS4A2) is prognostic in lung adenocarcinoma. , 2017, , .		0
15	Molecular Analysis of Lipid-Reactive Vδ1 γδ T Cells Identified by CD1c Tetramers. Journal of Immunology, 2016, 196, 1933-1942.	0.8	72
16	Bee venom processes human skin lipids for presentation by CD1a. Journal of Experimental Medicine, 2015, 212, 149-163.	8.5	98
17	Molecular basis of mycobacterial lipid antigen presentation by CD1c and its recognition by αβ T cells. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E4648-57.	7.1	49
18	The CD1 size problem: lipid antigens, ligands, and scaffolds. Cellular and Molecular Life Sciences, 2014, 71, 3069-3079.	5.4	32

#	Article	IF	Citations
19	CD1a, CD1b, and CD1c in Immunity Against Mycobacteria. Advances in Experimental Medicine and Biology, 2013, 783, 181-197.	1.6	46
20	CD1c tetramers detect ex vivo T cell responses to processed phosphomycoketide antigens. Journal of Experimental Medicine, 2013, 210, 729-741.	8.5	94
21	NKT Cells Stimulated by Long Fatty Acyl Chain Sulfatides Significantly Reduces the Incidence of Type 1 Diabetes in Nonobese Diabetic Mice. PLoS ONE, 2012, 7, e37771.	2.5	44
22	An Î±-galactosylceramide C20:2 N-acyl variant enhances anti-inflammatory and regulatory T cell-independent responses that prevent type 1 diabetes. Clinical and Experimental Immunology, 2010, 160, 185-198.	2.6	17
23	Innate Regulatory iNKT Cells. , 2008, , 501-524.		0
24	iNKT Cell Regulation of Type 1 Diabetes. Clinical Immunology, 2007, 123, S24.	3.2	0
25	The autoimmune regulator (Aire) controls iNKT cell development and maturation. Nature Medicine, 2006, 12, 624-626.	30.7	8
26	Protection from Type 1 Diabetes by Invariant NK T Cells Requires the Activity of CD4+CD25+ Regulatory T Cells. Journal of Immunology, 2006, 177, 3695-3704.	0.8	96
27	Role of Regulatory Invariant CD1d-Restricted Natural Killer T-Cells in Protection Against Type 1 Diabetes. Immunologic Research, 2005, 31, 177-188.	2.9	14
28	NKT Cells and Autoimmune Type 1 Diabetes. , 2005, , 43-53.		0
29	Interleukin-4 but not Interleukin-10 Protects Against Spontaneous and Recurrent Type 1 Diabetes by Activated CD1d-Restricted Invariant Natural Killer T-Cells. Diabetes, 2004, 53, 1303-1310.	0.6	80
30	Blockade of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Exacerbates Type 1 Diabetes in NOD Mice. Diabetes, 2003, 52, 1967-1975.	0.6	103